CONGRESS PRESENTATIONS
AIDS 2026
Rio de Janeiro, Brazil
Jul 26-31, 2026
-
ViiV-Sponsored Data
-
Cabotegravir Prevention
Acuipil C, et al.
Baseline demographics in the phase 2b registrational EXTEND 4M trial: evaluating a novel every-4-month cabotegravir formulation in a population who could benefit from PrEP
Armas-Kolostroubis L, et al.
No HIV acquisitions among women on cabotegravir long-acting injectable PrEP despite mostly short injection delays in the US OPERA Cohort
Brizzi M, et al.
Real-world experience using cabotegravir long-acting for HIV-1 pre-exposure prophylaxis in the united states from cross-sectional surveys and retrospective chart reviews: results from the CAPTIVATE study
Dupont-Benjamin L, et al.
Presence, Severity, Interference With Usual and Daily Life Activities and Bothersomeness of Injection Site Reactions With Cabotegravir vs Lenacapavir: Insights From Participant Reported Outcomes in the CLARITY Study
Glick JL, et al.
PrEP modality preference and socio-structural HIV vulnerability among transgender women and transfeminine persons in the United States: A latent class analysis
Glick JL, et al.
Socio-structural HIV vulnerability and PrEP willingness among transgender women and transfeminine persons in the United States: A latent class analysis
Herman GF, et al.
Real-world utilization and adherence of cabotegravir long-acting for HIV pre-exposure prophylaxis in the United States: updated results from the PrEPFACTS study using healthcare administrative claims data
Nelson KL, et al.
Participant and Provider Experiences With Long-Acting Cabotegravir vs Lenacapavir Injections: Results From the CLARITY Study
Pontes C, et al.
Evolving PrEP use in the long-acting injectable era: Findings from a cohort of transgender women in the United States and Puerto Rico, 2023–2025
Visnyei K, et al.
Operational insights for long-acting cabotegravir for HIV-1 pre-exposure prophylaxis: findings from the CAPTIVATE United States healthcare provider survey
-
Cabotegravir Treatment
Altamirano J, et al.
Resuppression and resistance after confirmed virologic failure among women on CAB+RPV LA in the OPERA Cohort
Hsu RK, et al.
Comparable virologic effectiveness with long-acting cabotegravir + rilpivirine vs. daily bictegravir/emtricitabine/tenofovir alafenamide in the US-based OPERA Cohort
Millner C, et al.
High virologic suppression among individuals on cabotegravir + rilpivirine long-acting with viral loads ≥50 copies/mL regardless of body mass index in the OPERA Cohort
-
Dolutegravir-based Regimens
Anderson K, et al.
Dolutegravir Markedly Improves 6- and 12-Month Viral Suppression in Children ≤5 Years, South Africa
Cahn P, et al.
Pooled analysis of on-study viremic events (VEs) and outcomes for dolutegravir + lamivudine (DTG+3TC) and comparator 3-drug regimens (3DRs) in clinical trials of people with HIV-1
Ghosn J, et al.
In VOGUE: DTG/3TC Demonstrates Non-Inferior Efficacy to BIC/FTC/TAF as First-Line Treatment
Greenberg L, et al.
Association between integrase inhibitors (INSTIs) and tenofovir alafenamide (TAF) and moderate chronic kidney disease (CKD) in the RESPOND HIV cohort collaboration
Neesgard B, et al.
Risk of fracture with contemporary antiretrovirals within the RESPOND Consortium
Pulido F, et al.
Who’s in VOGUE: a head‑to‑head clinical trial of dolutegravir/lamivudine (DTG/3TC) versus bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in adults naive to antiretroviral therapy (ART), including those with high viral loads
Sconza R, et al.
Cross-network, multicentre cohort study assessing real-world pregnancy and birth outcomes following prenatal dolutegravir exposure in Europe
-
Pipeline
-
Other Disease-Related Content
-
-
ViiV-Supported & Collaborative Data
-
Cabotegravir Prevention
Cholo FA, et al.
Experiences and motivations to use long-acting cabotegravir (CAB-LA) among pregnant and breastfeeding women accessing primary healthcare settings in South Africa: a qualitative study
Dong T, et al.
Estimating counterfactual background HIV incidence and cabotegravir efficacy versus a counterfactual placebo in HPTN 083 using Bayesian modeling
Dourado I, et al.
First evidence of adherence, safety, and effectiveness of long-acting injectable cabotegravir for PrEP among sexually and gender-diverse adolescents in Brazil
Drysdale RE, et al.
PrEP choice in South Africa: Determinants of CAB-LA uptake in a multi-product PrEP programme
Fonner V, et al.
Who switches and who stays when injectable PrEP becomes available? Results from CATALYST- an implementation study among women in sub-Saharan Africa
Jacobs J, et al.
Challenges in Early HIV Detection During CAB‑LA PrEP: Characterization of Inconclusive Serological Results in ImPrEP CAB Brasil
Martin CE, et al.
PrEP method switching within multi-method PrEP services in primary care settings in South Africa
Martin CE, et al.
PrEP use within multi-method PrEP services in primary care settings in South Africa
Musvipwa FM, et al.
User experiences with long-acting injectable CAB-LA PrEP in South Africa: qualitative insights into acceptability, motivations for use, and challenges
Naidoo N, et al.
Uptake and use of injectable PrEP among pregnant and breastfeeding women: Results from a prospective cohort of women in South Africa offered CAB-LA in the context of method choice
Pimenta MC, et al.
Implementing long-acting cabotegravir PrEP: Insights from healthcare professionals in public health services in Brazil
Segawa I, et al.
“I just made my own choice”: Women’s decision-making in the context of HIV PrEP choice in Eastern and Southern Africa
Shahmanesh M, et al.
"I missed my appointment, but I have peace of mind": HIV self-testing in the context of community-based delivery of long-acting HIV Pre-Exposure prophylaxis in rural South Africa
Wang H, et al.
Uncovering direct influences on the intention to use long-acting injectable PrEP among MSM to support its upcoming rollout across Europe: A systematic review of reviews and a Bayesian network analysis
-
Cabotegravir Treatment
Alford K, et al.
Acceptability and experience of long-acting injectable cabotegravir and rilpivirine in people with HIV and cognitive impairment
Alford K, et al.
Real-world acceptability and experiences of long-acting injectable cabotegravir and rilpivirine: client perspectives and experiences
Eu B, et al.
High acceptability and persistence of long-acting injectable cabotegravir/rilpivirine treatment in Australian primary care: early real-world implementation data from people living with HIV and healthcare workers
-
Dolutegravir-based Regimens
Brites C, et al.
Frequency and type of adverse events death in People with HIV Treated with Dolutegravir or Comparator Drugs in the CODE Cohort, Brazil
Cahn P, et al.
Incidence and outcomes of AIDS-defining illnesses after dolutegravir/lamivudine initiation in advanced HIV in the DOLCE Study
Di Gregorio S, et al.
The body composition signature of switching to BIC/FTC/TAF or DTG/3TC over 96 weeks
Matubu TA, et al.
Inflammatory plasma proteins are differentially expressed in pregnant women on ART and can predict adverse pregnancy outcomes
Murray-Krezan C, et al.
Viral suppression associated with DTG treatment in Brazil: results from CODE, a country-wide cohort study
Ombajo LA, et al.
No reactivation of Hepatitis B in African patients on a tenofovir free regimen for the treatment of HIV: results from the switch to DTG/3TC (Sungura) study
Page K, et al.
Body weight and BMI changes associated with DTG treatment in Brazil: results from CODE, a country-wide cohort study
Rolle C-P, et al.
Long-term efficacy, safety and persistence of dolutegravir/lamivudine vs. bictegravir/emtricitabine/tenofovir alafenamide among virologically suppressed adults-results from the 144-week observational extension phase of the DYAD study
Wang R, et al.
The impact of archived HIV-1 drug resistance on maintenance of virologic suppression through Week 48 in children aged 2 to <15 years receiving DTG/3TC: PENTA-21 intensive pharmacokinetic sub-study
-
Other Disease-Related Content
Devonald M, et al.
Complex support needs, adherence challenges and interest in long-acting HIV treatment among Trans, Non-Binary, and Gender-Diverse people living with HIV: findings from the coproduced ‘Ask Us Europe’ survey
Devonald M, et al.
Interest of people living with HIV in Europe in future long-acting modalities: Ask Us Europe results
Devonald M, et al.
Perspectives of people living with HIV in Europe on their clinical consultations: an equity analysis
-
